Drugs / imarikiren
last change Nov 2018 re-read 2 minutes ago

imarikiren

Small molecule targets REN via inhibition

Developed for
type 2 diabetes mellitus
Investigated by
Takeda

Trials 3 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02367872 Mar 2015 → Jun 2016 impaired renal function disease Takeda Completed No outcome recorded
Phase 1 NCT02370615 Feb → Apr 2015 Takeda Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02332824 Oct 2014 → Aug 2016 type 2 diabetes mellitus Takeda Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as imarikiren Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor.” PMID 30194585 Nov 2018
Known as IMARIKIREN HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL3990145
Known as Imarikirene ChEMBL registry synonym — accepted as the source's own label CHEMBL3990145
Known as Imarikireno ChEMBL registry synonym — accepted as the source's own label CHEMBL3990145
Known as SCO-272 “Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor.” PMID 30194585 Nov 2018
Known as TAK-272 “Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor.” PMID 30194585 Nov 2018
2

NCT02332824

NCT02370615

Known as TAK-272 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL3990145
Action Inhibit “Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor.” PMID 30194585 Nov 2018
Modality Small molecule CHEMBL3990145
Route Oral “All participants were administered tablets, orally at the same time each day for 12 weeks” NCT02332824
Target REN “Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor.” PMID 30194585 Nov 2018